Evidence map›Paper›PMID 38935635›Full record

ArticlePloS one2024

A reliable and quick method for screening alternative splicing variants for low-abundance genes.

Yanchun Zhang, Wubin Qu, Ruifen Yan, Huqi Liu, Chenggang Zhang, Zhihui Li, Guofu Dong

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yanchun ZhangDepartment of Blood Transfusion Medicine, The Seventh Medical Center of PLA General Hospital, Beijing, China.
Wubin QuLaboratory of Electromagnetic Biological Effects, Beijing Institute of Radiation and Medicine, Beijing, China.
Ruifen YanLaboratory of Electromagnetic Biological Effects, Beijing Institute of Radiation and Medicine, Beijing, China.
Huqi LiuCollege of Life Science, Northwest Agriculture and Forest University, Yangling, China.
Chenggang ZhangLaboratory of Electromagnetic Biological Effects, Beijing Institute of Radiation and Medicine, Beijing, China.ORCID 0000-0002-4521-3304
Zhihui LiLaboratory of Electromagnetic Biological Effects, Beijing Institute of Radiation and Medicine, Beijing, China.ORCID 0000-0002-7042-5966
Guofu DongLaboratory of Electromagnetic Biological Effects, Beijing Institute of Radiation and Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alternative splicing (AS) is a universal phenomenon in eukaryotes, and it is still challenging to identify AS events. Several methods have been developed to identify AS events, such as expressed sequence tags (EST), microarrays and RNA-seq. However, EST has limitations in identifying low-abundance genes, while microarray and RNA-seq are high-throughput technologies, and PCR-based technology is needed for validation. To overcome the limitations of EST and shortcomings of high-throughput technologies, we established a method to identify AS events, especially for low-abundance genes, by reverse transcription (RT) PCR with gene-specific primers (GSPs) followed by nested PCR. This process includes two major steps: 1) the use of GSPs to amplify as long as the specific gene segment and 2) multiple rounds of nested PCR to screen the AS and confirm the unknown splicing variants. With this method, we successfully identified three new splicing variants, namely, GenBank Accession No. HM623886 for the bdnf gene (GenBank GeneID: 12064), GenBank Accession No. JF417977 for the trkc gene (GenBank GeneID: 18213) and GenBank Accession No. HM623888 for the glb-18 gene (GenBank GeneID: 172485). In addition to its reliability and simplicity, the method is also cost-effective and labor-intensive. In conclusion, we developed an RT-nested PCR method using gene-specific primers to efficiently identify known and novel AS variants. This approach overcomes the limitations of existing methods for detecting rare transcripts. By enabling the discovery of new isoforms, especially for low-abundance genes, this technique can aid research into aberrant splicing in disease. Future studies can apply this method to uncover AS variants involved in cancer, neurodegeneration, and other splicing-related disorders.

Indexed as

Alternative SplicingBrain-Derived Neurotrophic FactorDNA PrimersHumansReverse Transcriptase Polymerase Chain ReactionBrain-Derived Neurotrophic FactorDNA Primers

Identifiers

PMID38935635
PMCPMC11210779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.